Skip to main content

Table 2 Successfully validated dysregulated circRNAs in prostate cancer

From: The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

 

Cohort 1

Cohort 2

Upregulated in PC vs. AN

Adj. P value

FC

AUC

Adj. P value

FC

AUC

circABCC4

0.0004

1.62

0.71

< 0.0001

2.31

0.78

circZNF577

0.01

1.33

0.64

0.04

1.56

0.64

Downregulated in PCvs. AN

Adj.value

FC

AUC

Adj.value

FC

AUC

circFAT3

< 0.0001

− 3.14

0.82

< 0.0001

− 3.79

0.86

circITGA7

< 0.0001

− 2.31

0.75

< 0.0001

− 2.96

0.81

circATRNL1

< 0.0001

− 2.25

0.78

< 0.0001

− 5.54

0.85

circSLC45A4

< 0.0001

− 2.17

0.82

< 0.0001

− 1.96

0.85

circRNASEH2B

< 0.0001

− 2.08

0.81

< 0.0001

− 2.00

0.81

circSEMA3C

< 0.0001

− 2.07

0.80

< 0.0001

− 2.25

0.82

circSLC8A1

< 0.0001

− 2.04

0.76

< 0.0001

− 2.12

0.87

circARHGAP10

< 0.0001

− 2.01

0.79

< 0.0001

− 1.92

0.83

Downregulated in MPCvs. LPC

value

FC

AUC

value

FC

AUC

circMKLN1

0.0004

− 2.03

0.77

0.028

− 1.36

0.64

circN4BP2L2

0.03

− 1.77

0.67

< 0.0001

− 1.53

0.76

circZNF532

0.01

− 1.76

0.69

0.0002

− 1.78

0.74

circCDYL2

0.04

− 1.60

0.66

< 0.0001

− 2.19

0.76

circARHGAP10

0.001

− 2.13

0.76

0.001

− 1.74

0.71

  1. Results for the top dysregulated candidates in PC vs. AN and in MPC vs. LPC, respectively. For upregulated circRNAs in PC, all candidates significant in cohort 1 are shown. For downregulated circRNAs in PC, candidates with fold change > − 2 in cohort 1 are shown. For dysregulated circRNAs in LPC vs. MPC, candidates significant (uncorrected P < 0.05) in both cohorts 1 and 2 are shown (all downregulated)